Pancreatic Cancer Research

ResearcherOntario Institute for Cancer ResearchActive in the last 2 years

Jennifer Jane Knox

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3474-6647; OpenAlex author ID A5068644454. Sources: ClinicalTrials.gov.

Their work

Papers
52 (first author 3, last author 4)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
151
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 4 papers · 2019: 2 papers · 2020: 7 papers, 2 trials · 2021: 11 papers · 2022: 7 papers · 2023: 3 papers · 2024: 1 paper · 2025: 8 papers · 2026: 8 papers

Papers 50 of 52

  1. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarc… Co-author DOI 10.1038/s41467-026-70120-z↗
  2. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  3. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  4. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Last author DOI 10.1200/jco-25-02199↗
  5. Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer. First author DOI 10.3389/frai.2026.1873681↗
  6. Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.04.07.717011↗
  7. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  8. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  9. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Co-author DOI 10.1002/1878-0261.13747↗
  10. Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113176↗
  11. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  12. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  13. Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations Co-author DOI 10.1101/2025.08.15.670565↗
  14. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  15. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  16. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  17. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study. Last author DOI 10.3390/curroncol31050194↗
  18. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
  19. Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. Co-author DOI 10.1136/jclinpath-2021-207781↗
  20. hENT1 as a Predictive Biomarker in PDAC-Response. Co-author DOI 10.1158/1078-0432.ccr-23-0887↗
  21. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-022-09057-y↗
  22. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal a… Co-author DOI 10.1038/s41467-022-32591-8↗
  23. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Co-author DOI 10.1038/s41467-022-33718-7↗
  24. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1272↗
  25. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
  26. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo-22-86↗
  27. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? Co-author DOI 10.6004/jnccn.2021.7107↗
  28. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. Co-author DOI 10.1007/s00330-021-07899-6↗
  29. Spatially confined sub-tumor microenvironments in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.09.022↗
  30. A Risk Score Model for Locoregional Recurrence Following Upfront Surgery for Pancreatic Adenocarcinoma: Implications for Adjuvant Therapy. Co-author DOI 10.1016/j.clon.2021.03.007↗
  31. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. Co-author DOI 10.1016/j.ctrv.2021.102310↗
  32. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Co-author DOI 10.1038/s41598-021-94544-3↗
  33. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  34. Simulated dose painting of hypoxic sub-volumes in pancreatic cancer stereotactic body radiotherapy. Co-author DOI 10.1088/1361-6560/ac215c↗
  35. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  36. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In? Co-author DOI 10.1158/1078-0432.ccr-20-1042↗
  37. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Co-author DOI 10.1158/1078-0432.ccr-20-2831↗
  38. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy. Co-author DOI 10.1177/0846537120968782↗
  39. Severe optic neuropathy as the presenting sign of leptomeningeal carcinomatosis from pancreatic cancer. First author DOI 10.1016/j.jcjo.2020.04.023↗
  40. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  41. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  42. Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1543↗
  43. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-2803↗
  44. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3724↗
  45. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1439↗
  46. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Co-author DOI 10.1016/j.ccell.2018.12.010↗
  47. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-0191↗
  48. Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Co-author DOI 10.1007/s10897-018-0212-1↗
  49. Locally advanced pancreatic cancer: An emerging entity. First author DOI 10.1016/j.currproblcancer.2017.10.006↗
  50. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Last author DOI 10.1158/1078-0432.ccr-17-2994↗

Trials 2

  1. Pancreatic Adenocarcinoma Signature Stratification for Treatment Study chair NCT04469556↗
  2. GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma Principal investigator NCT04472910↗

Closest collaborators

The 25 strongest of 151 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 45 shared papers, 2018–2026 · strength 5.86
  2. Grainne Mary O'Kane · 41 shared papers, 2018–2026 · strength 5.38
  3. Faiyaz Notta · 33 shared papers, 2018–2026 · strength 4.46
  4. Robert C. Grant · 30 shared papers, 2018–2026 · strength 4.13
  5. Sandra Elisabeth Fischer · 23 shared papers, 2018–2026 · strength 2.69
  6. George Zogopoulos · 18 shared papers, 2018–2026 · strength 1.99
  7. Daniel John Renouf · 16 shared papers, 2019–2026 · strength 1.97
  8. Erica S. Tsang · 11 shared papers, 2021–2026 · strength 1.72
  9. Barbara T. Grünwald · 12 shared papers, 2020–2026 · strength 1.72
  10. David F. Schaeffer · 14 shared papers, 2019–2026 · strength 1.65
  11. James Thomas Topham · 13 shared papers, 2019–2026 · strength 1.56
  12. Joanna M. Karasinska · 12 shared papers, 2019–2026 · strength 1.44
  13. Michelle Chan‐Seng‐Yue · 9 shared papers, 2019–2026 · strength 1.26
  14. Yifan Wang · 11 shared papers, 2020–2025 · strength 1.21
  15. Spring Holter · 10 shared papers, 2018–2026 · strength 1.19
  16. Ayelet Borgida · 11 shared papers, 2018–2026 · strength 1.18
  17. Ravi Ramjeesingh · 7 shared papers, 2021–2026 · strength 1.06
  18. Mustapha Ali Tehfe · 6 shared papers, 2022–2026 · strength 0.94
  19. Eugenia Flores Figueroa · 6 shared papers, 2020–2026 · strength 0.92
  20. Raymond Jang · 6 shared papers, 2021–2025 · strength 0.91
  21. Elizabeth M. Jaffee · 3 shared papers, 1 shared trial, 2020–2026 · strength 0.89
  22. David Arthur Tuveson · 6 shared papers, 2020–2026 · strength 0.86
  23. Oliver F. Bathe · 6 shared papers, 2021–2025 · strength 0.76
  24. Rachel Anne Goodwin · 6 shared papers, 2021–2025 · strength 0.76
  25. Malcolm J. Moore · 7 shared papers, 2016–2025 · strength 0.75

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.